Stimulin
ANTIDIABETICS: Glimepiride
Indication
Monotherapy: Stimulin (Glimepiride) is indicated as monotherapy as an adjunct to diet and exercise for the management of Type 2 (non-insulin dependent) diabetes mellitus (NIDDM) in patients whose hyperglycemia cannot be controlled by diet and exercise alone.
Combination Therapy: Stimulin (Glimepiride) may be used in combination with metformin when diet, exercise and Stimulin (Glimepiride) or metformin alone do not result in adequate glycemic control.Stimulin (Glimepiride) is also indicated for use in combination with insulin to lower blood glucose whose hyperglycemia cannot be controlled by diet and exercise in conjunction with an oral hypoglycemic agent.
Contraindication
Stimulin (Glimepiride) is contraindicated in patients with known hypersensitivity to the drug, diabetic ketoacidosis.
Dosage & Administration
Dosage of Stimulin (Glimepiride) is individualized carefully based on patient response and tolerance. The goal of therapy with Stimulin (Glimepiride) is to achieve the desired blood glucose level using the lowest effective dosage of Stimulin (Glimepiride), when used either as monotherapy or combined with metformin or insulin.
Initial Dosage in PreviouslyUntreated Patients: The usual initial adult dosage of Stimulin (Glimepiride) is 1-2 mg once daily administered orally with breakfast or the first main meal.Initial Dosage in Patients Transferred from Other
Antidiabetic Agents: When transferring from most sulphonylurea antidiabetic agents to Stimulin (Glimepiride), a transition period is generally not required, and administration of the sulphonylurea antidiabetic agent may be discontinued abruptly.
For the management of Type 2 (non- insulin dependent) diabetes mellitus (NIDDM) in adults previously receiving other sulphonylurea antidiabetic agents, the initial dosage of Stimulin (Glimepiride) should be 1-2 mg once daily by mouth.
Maintenance Dosage: The usual maintenance dosage of Stimulin (Glimepiride) for the management of Type 2 (non-insulin dependent) diabetes mellitus (NIDDM) ranges from 1-4 mg once daily by mouth. The maximum recommended dosage is 8 mg once daily. After a dosage of 2 mg is reached, subsequent dosage is increased at increments of mg at 1- to 2-week intervals based on the patient\’s blood glucose response.
Concomitant Stimulin (Glimepiride) and Metformin Therapy: With concomitant Stimulin (Glimepiride) and metformin therapy, glycemic control may be obtained by adjusting the dosage of the minimum effective dosage for each drug.
Concomitant Stimulin (Glimepiride) and Insulin Therapy: The recommended dosage is 8 mg once daily orally with the first main meal with low-dose of insulin.
Side Effect
The incidence of hypoglycemia with Stimulin (Glimepiride) is 0.9- 1.7%. Nausea, vomiting, diarrhoea, dizziness, headache, urticaria may occur.
Drug Interaction
The hypoglycemic action of Stimulin (Glimepiride) may be potentiated by NSAlDs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid, monoamino oxidase inhibitors, and beta adrenergic blocking agents. Certain drugs eg diuretics, corticosteroids, phenothiazines, thyroid products, estrogen, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, isoniazid may produce hyperglycemia ultimately leading to loss of control with Stimulin (Glimepiride).
Stimulin (Glimepiride) should not be used during pregnancy and lactation.
Presentation
Stimulin 1 Tablet: Each box contains 3×10\’s tablets in blister packs.
Stimulin 2 Tablet: Each box contains 3×10\’s tablets in blister packs.
